 AN INVESTIGATIONAL DRUG, PF-02341066 IS BEING STUDIED VERSUS STANDARD OF CARE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH A SPECIFIC GENE PROFILE INVOLVING THE ANAPLASTIC LYMPHOMA KINASE ALK GENE: 